Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
A phase II study of [90Y]yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy
Daniel Kahn; J. Christopher Austin; Robert T. Maguire; Sara J. Miller; Jack Gerstbrein; Richard D. Williams (Profiled Author: James (Christopher) Austin)
Cancer Biotherapy and Radiopharmaceuticals. 1999;14(2):99-111.Abstract
There is currently no curative therapy for men who have disseminated prostate cancer following failed radical prostatectomy. The purpose of this trial was to investigate systemic radioimmunotherapy in these men. Eight patients with occult metastatic prostate cancer following radical prostatectomy as evidenced solely by a rising serum PSA and evidence of soft tissue lesions outside the prostatic fossa detected by an [111I]indium capromab pendetide scan received an infusion of 10 mg of capromab pendetide labeled with 9 mCi/m2 of [90Y]yttrium. Serum PSA was used to measure response rate. There were no complete or partial responses by PSA criteria. Significant unexpected bone marrow toxicity developed in the first 6 of 8 patients treated. The last two patients received co-infusion o federate calcium disodium in an effort to decrease marrow suppression. In these two patients less marrow toxicity was seen. Repeat 111In-capromab pendetide scans were uninterpretable due to grossly altered whole-body biodistribution of the radioimmunoconjugate. Retrospective analysis of serial PSA values after closure of the study showed a decrease in the log slope PSA for seven of eight patients following radioimmunotherapy, with a statistically significant change in the mean log slope (p = 0.01). The clinical significance of this small but measurable change is uncertain. We conclude that radioimmunotherapy for occult metastatic prostate cancer using 90Y- capromab-pendetide at the dose described does not lower serum PSA, is associated with significant hematologic toxicity, and leads to complexation of the immunoconjugate following subsequent capromab pendetide infusion.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Tomasz M. Beer; Mark Garzotto; Kristi M. Eilers; Dianne Lemmon; Emily M. WersingerUrology. 2004;63(2):342-347.
Mark Garzotto; Celestia S. Higano; Catherine O'Brien; Brooks L. S. Rademacher; Nicole Janeba; Ladan Fazli; Paul H. Lange; Stephen Lieberman; Tomasz M. BeerCancer. 2010;116(7):1699-1708.
Colleen A. Lawton; Michelle DeSilvio; Mack Roach III; Valery Uhl; Robert Kirsch; Michael Seider; Marvin Rotman; Christopher Jones; Sucha Asbell; Richard Valicenti; et al.
An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation InteractionsInternational Journal of Radiation Oncology Biology Physics. 2007;69(3):646-655.
Appears in this Document